- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02596880
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics (SD100)
April 18, 2023 updated by: Reza Malekzadeh, MD, Tehran University of Medical Sciences
Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin
The investigators will treat 100 patients with cirrhosis due to hepatitis C with sofosbuvir 400 mg daily, daclatasvir 60 mg daily and weight-based ribavirin (1000 mg/d if <75 kg, 1200 mg/d if >75 kg, divided in two daily doses) for 12 weeks and calculate the sustained viral response rate at 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cirrhosis due to Hepatitis C presents a rather difficult treatment problem as many cannot tolerate interferon, the previous standard of treatment.
The new direct acting antivirals have provided these patients with a new hope.
One such combination is sofosbuvir (SOF) 400 mg and daclatasvir (DCV) 60 mg given once daily with or without weight-based ribavirin (RBV) for 12 or 24 weeks.
The current recommendation for cirrhotics is SOF/DCV/RBV for 24 weeks but that recommendation is based on the lack of data for shorter periods.
In order to evaluate the response rate to the combination of SOF/DCV/RBV the investigators decided to treat 100 HCV cirrhotics with this combination for 12 weeks.
Subjects include genotype 1 and 3 patients, the prevalent genotypes in Iran.
Patients with Model for End stage Liver Disease (MELD) > 20 are excluded.
The investigators will calculate the sustained viral response rate at 12 weeks (SVR12).
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 14117
- Shariati Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Positive qualitative HCV RNA test on two occasions at least 6 months apart
- Cirrhosis proven by either of: 1. Liver biopsy, 2. Liver elasticity > 12 kilopascal (KPa), 3. Clinical certainty (ascites, splenomegaly, small liver, low albumin, low platelet)
Exclusion Criteria:
- Renal failure (eGFR < 30 cc/min),
- MELD score > 20,
- Child's C (CTP score > 12),
- Heart rate < 50/min,
- Taking amiodarone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Subjects will receive sofosbuvir, daclatasvir and ribavirin
|
400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
Other Names:
60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
Other Names:
1000 mg/day if <75 kg, 1200 mg/day for >75 kg.
Divided into two daily doses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The sustained viral response rate
Time Frame: week 24 (12 weeks after end of treatment)
|
Qualitative HCV RNA polymerase chain reaction (PCR)
|
week 24 (12 weeks after end of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse drug events
Time Frame: week 2, 4, 8, 12, 24
|
Questionnaire
|
week 2, 4, 8, 12, 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
November 3, 2015
First Submitted That Met QC Criteria
November 3, 2015
First Posted (Estimate)
November 4, 2015
Study Record Updates
Last Update Posted (Actual)
April 20, 2023
Last Update Submitted That Met QC Criteria
April 18, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Fibrosis
- Hepatitis
- Hepatitis A
- Hepatitis C
- Liver Cirrhosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Sofosbuvir
- Ribavirin
Other Study ID Numbers
- 94-02-159-30278
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
University Health Network, TorontoCompletedChronic Hepatitis C InfectionCanada
Clinical Trials on Sofosbuvir
-
Assiut UniversityUnknown
-
Radboud University Medical CenterWithdrawnHCVNetherlands, Germany
-
Icahn School of Medicine at Mount SinaiGilead SciencesCompletedHepatitis C | CryoglobulinemiaUnited States
-
University of California, San FranciscoCompletedHepatitis C | Transplantation Disease TransmissionUnited States
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
Fondazione Italiana Linfomi ONLUSCompletedHepatitis C | Indolent B-cell LymphomaItaly
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Hepatitis C (Disorder)
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
Ain Shams UniversityRecruitingChronic HCV InfectionEgypt
-
Brigham and Women's HospitalRecruiting